We investigate patterns in common ownership networks between firms that are active in the US pharmaceutical industry for the period 2004-2014. Our main findings are that "brand firms" - i.e. firms that have R&D capabilities and launch new drugs - exhibit relatively dense common ownership...

Common ownership - where several firms are (partially) owned by the same investors - and its impact on product market competition has recently drawn much attention. This paper focuses on its implications for market entry. Specifically, we consider the entry decisions of generic pharmaceutical...

We investigate patterns in common ownership networks between firms that are active in the U.S. pharmaceutical industry for the period 2004–2014. Our main findings are that “brand firms”—that is, firms that have research and development capabilities and launch new drugs—exhibit...

Ownership of publicly listed German companies has undergone significant changes in recent years. The aim of this report is to document these trends since 2007 and analyze the extent to which firms that compete in the same product market are owned by the same investors, which is known as common...

Die Eigentümerstrukturen börsennotierter deutscher Unternehmen haben sich in den letzten Jahren deutlich verändert. Von besonderem Interesse ist dabei das Phänomen der gemeinsamen Eigentümerstrukturen, das international mit dem Begriff "Common Ownership" bezeichnet wird. Dabei werden...

Die Bereitstellung eines sicheren und wirksamen Impfstoffs gegen Covid-19 ist von zentraler Bedeutung für die Aufhebung der Eindämmungsmaßnahmen im öffentlichen Leben. Um den Zugang zu Impfstoffen zu sichern, schließen Regierungen mit Impfstoffunternehmen spezielle Verträge, "Advance...

The deployment of a safe and effective vaccine for Covid-19 will be central to lifting containment measures. In a bid to speed up vaccine deployment, governments are entering into 'Advance Purchase Agreements' (APAs) with vaccine companies to secure access to vaccine doses. We document and...

This paper analyzes M&A patterns of R&D projects in the antidiabetics industry. For this purpose, we construct a database with all corporate individual antidiabetics R&D projects over the period 1997 - 2017, and add detailed information on firms' technology dimension using patent information,...

We analyse the effects of investment decisions and firms’ internal organisation on the efficiency and stability of horizontal mergers. In our framework synergies are endogenous and there might be internal conflict within merged firms. We show that often stable mergers do not lead to more...

Merger activity is intense during economic booms and subdued during recessions. This paper provides a non-financial explanation for this observable pattern. We construct a model in which the target—by setting the takeover price—screens the acquirer on his (expected) ability to realize...